Camlin Fine Sciences
CAMLINFINE NSE
Camlin Fine Sciences
ChemicalsNSE: CAMLINFINE BSE: 532834 Specialty Chemicals
Key Fundamentals
MicrocapSpecialty ChemicalsChemicalsMarket Cap
₹1,957 Cr
Volatility
Moderate
P/E Ratio
350.62
EBITDA
₹136 Cr
Return on Equity
-3.15%
Debt to Equity
0.69
Book Value
₹54.01
52W High
₹235
52W Low
₹96.21
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company's working capital requirements have reduced from 35.3 days to 22.6 days
Weaknesses
4- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 7.74% over past five years.
- Company has a low return on equity of -6.99% over last 3 years.
- Earnings include an other income of Rs.63.6 Cr.
Growth Rate
Revenue Growth
6.59% higher than
3Y
Net Income Growth
-148% lower than
3Y
Cash Flow Change
257% higher than
3Y
ROE
-142% lower than
3Y
ROCE
-77.82% higher than
3Y
EBITDA Margin (Avg.)
-44.95% lower than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 420 | 406 | 386 | 377 | 381 | 417 | 431 | 432 | 408 | 460 | 441 | 425 | 520 |
| Expenses | 381 | 381 | 363 | 345 | 352 | 366 | 375 | 370 | 387 | 427 | 420 | 404 | 511 |
| Operating Profit | 39 | 25 | 23 | 31 | 29 | 52 | 56 | 62 | 20 | 33 | 21 | 21 | 9 |
| OPM % | 9% | 6% | 6% | 8% | 8% | 12% | 13% | 14% | 5% | 7% | 4.7% | 5% | 1.8% |
| Other Income | 6 | 2 | 2 | -96 | -15 | -151 | -8 | -22 | 0 | -4 | -24 | 103 | -10 |
| Interest | 10 | 20 | 14 | 16 | 23 | 26 | 34 | 15 | 15 | 19 | 17 | 23 | 14 |
| Depreciation | 19 | 19 | 21 | 13 | 15 | 17 | 14 | 17 | 16 | 19 | 16 | 21 | 19 |
| PBT | 16 | -12 | -10 | -94 | -23 | -142 | 0 | 8 | -11 | -9 | -37 | 80 | -34 |
| Tax % | 25% | 72% | 47% | -13% | 48% | -18% | 2164% | 98% | 0% | 65% | 0% | -8% | -1% |
| Net Profit | 12 | -21 | -14 | -82 | -35 | -116 | -7 | 0 | -11 | -15 | -37 | 86 | -34 |
| EPS in Rs | 0.83 | -1.03 | -0.63 | -4.11 | -1.81 | -5.33 | -0.22 | -0.04 | -0.53 | -0.76 | -1.89 | 4.59 | -1.65 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 558 | 489 | 534 | 721 | 892 | 1,049 | 1,187 | 1,412 | 1,682 | 1,454 | 1,629 | 1,723 | 1,845 |
| Expenses | 474 | 397 | 502 | 705 | 819 | 914 | 1,000 | 1,254 | 1,471 | 1,284 | 1,402 | 1,605 | 1,761 |
| Operating Profit | 84 | 92 | 32 | 16 | 73 | 135 | 187 | 158 | 211 | 170 | 227 | 118 | 84 |
| OPM % | 15% | 19% | 6% | 2.2% | 8% | 13% | 16% | 11% | 13% | 12% | 14% | 7% | 4.6% |
| Other Income | 9 | -1 | 14 | 12 | 14 | 3 | 5 | 33 | -4 | -142 | -218 | 59 | 64 |
| Interest | 24 | 24 | 31 | 32 | 41 | 48 | 42 | 41 | 64 | 70 | 107 | 83 | 73 |
| Depreciation | 16 | 17 | 22 | 27 | 29 | 33 | 44 | 56 | 63 | 56 | 61 | 71 | 75 |
| PBT | 53 | 50 | -6 | -31 | 17 | 58 | 105 | 94 | 80 | -99 | -159 | 23 | 0 |
| Tax % | -4% | 28% | -26% | -22% | 82% | 49% | 38% | 36% | 50% | 6% | 0% | -2% | — |
| Net Profit | 55 | 36 | -4 | -24 | 3 | 30 | 65 | 60 | 40 | -105 | -158 | 24 | 1 |
| EPS in Rs | 5.11 | 3.3 | -0.96 | -2.18 | 0.04 | 2.23 | 3.56 | 3.45 | 2.96 | -4.94 | -7.4 | 1.44 | 0.29 |
| Div. Payout % | 8% | 12% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 12 | 12 | 12 | 13 | 16 | 16 | 17 | 19 | 19 |
| Reserves | 125 | 167 | 202 | 359 | 359 | 391 | 631 | 732 | 804 | 848 | 883 | 1,022 |
| Borrowings | 160 | 180 | 331 | 373 | 461 | 539 | 550 | 646 | 801 | 683 | 652 | 720 |
| Other Liabilities | 131 | 123 | 126 | 273 | 255 | 290 | 282 | 396 | 425 | 424 | 467 | 559 |
| Total Liabilities | 426 | 479 | 669 | 1,016 | 1,087 | 1,232 | 1,475 | 1,790 | 2,045 | 1,972 | 2,020 | 2,320 |
| Fixed Assets | 106 | 140 | 201 | 278 | 272 | 306 | 584 | 601 | 858 | 816 | 704 | 887 |
| CWIP | 3 | 25 | 8 | 14 | 59 | 179 | 24 | 215 | 43 | 46 | 10 | 33 |
| Investments | 1 | 1 | 19 | 115 | 11 | 7 | 7 | 7 | 8 | 8 | 61 | 30 |
| Other Assets | 316 | 313 | 442 | 609 | 745 | 740 | 861 | 966 | 1,136 | 1,102 | 1,246 | 1,370 |
| Total Assets | 426 | 479 | 669 | 1,016 | 1,087 | 1,232 | 1,475 | 1,790 | 2,045 | 1,972 | 2,020 | 2,320 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 46 | 72 | -9 | -15 | -9 | 86 | 117 | 145 | 51 | 139 | 23 | 82 |
| Investing | -26 | -66 | -70 | -149 | -2 | -90 | -133 | -249 | -125 | -66 | -75 | -53 |
| Financing | -15 | -7 | 91 | 182 | 26 | 3 | 39 | 136 | 60 | -86 | 76 | -25 |
| Net Cash Flow | 4 | -1 | 13 | 18 | 15 | -1 | 23 | 32 | -14 | -13 | 24 | 4 |
| Free Cash Flow | 19 | 5 | -39 | -34 | -78 | -48 | 34 | -68 | -93 | 79 | -19 | 20 |
| CFO/OP | 68 | 91 | 5 | -33 | 10 | 77 | 82 | 111 | 34 | 110 | 27 | 90 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 74 | 56 | 99 | 104 | 86 | 88 | 83 | 77 | 66 | 72 | 74 | 79 |
| Inventory Days | 184 | 311 | 277 | 207 | 219 | 204 | 200 | 178 | 255 | 256 | 234 | 199 |
| Days Payable | 144 | 171 | 110 | 154 | 127 | 119 | 99 | 112 | 129 | 154 | 180 | 200 |
| Cash Conversion Cycle | 114 | 196 | 266 | 157 | 178 | 173 | 184 | 143 | 192 | 174 | 127 | 78 |
| Working Capital Days | 12 | 1 | -6 | 19 | 43 | 22 | 55 | 40 | 42 | 51 | 33 | 23 |
| ROCE % | 28% | 24% | 5% | 0% | 7% | 11% | 13% | 10% | 10% | 8% | 12% | 5% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Camlin Fine Sciences insights
64 extracted metrics + investor summaries across FY07–FY26.
Documents
1
Disclosure Of Events Or Information
1d - Diphenol Plant shut; May 23 fire caused INR 2 crore loss, restart expected within 48 hours. 1d - Diphenol Plant shut; May 23 fire caused INR 2 crore loss, restart expected within 48 hours.
2
Disclosure Of Events Or Information
1d - Camlin Fine Sciences shuts Diphenol Plant and reports a fire, causing Rs 2 crore loss; restart expected in 48 hours. 1d - Camlin Fine Sciences shuts Diphenol Plant and reports a fire, causing Rs 2 crore loss; restart expected in 48 hours.
3
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
8 May - Members approved increase in authorized share capital via postal ballot on May 7, 2026. 8 May - Members approved increase in authorized share capital via postal ballot on May 7, 2026.
4
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
8 May - Members approved increase in authorized share capital via postal ballot on May 7, 2026. 8 May - Members approved increase in authorized share capital via postal ballot on May 7, 2026.
5
Press Release Issued By The Company.
4 May - Camlin files mandatory tender offer for remaining Vinpai shares at EUR 3.60 on May 4, 2026. 4 May - Camlin files mandatory tender offer for remaining Vinpai shares at EUR 3.60 on May 4, 2026.
Frequently Asked Questions about Camlin Fine Sciences
What does Camlin Fine Sciences Ltd do?
Camlin Fine Sciences is engaged in the Business of Speciality Chemicals.
Where is Camlin Fine Sciences Ltd (CAMLINFINE) listed?
Camlin Fine Sciences Ltd trades as CAMLINFINE on the NSE and under code 532834 on the BSE.
Which sector does Camlin Fine Sciences Ltd belong to?
Camlin Fine Sciences Ltd is classified under the Chemicals sector, in the Specialty Chemicals industry.
What is the market capitalisation of Camlin Fine Sciences Ltd?
Camlin Fine Sciences Ltd has a market capitalisation of ₹1,957 Cr, which places it in the Small Cap band.
What is the PE ratio of Camlin Fine Sciences Ltd?
Camlin Fine Sciences Ltd trades at a PE ratio of 350.62, against a book value of ₹54.01 per share.
What is the 52-week high and low of Camlin Fine Sciences Ltd?
Over the last 52 weeks Camlin Fine Sciences Ltd has traded between ₹96.21 and ₹235.
What is the Return on Equity (ROE) of Camlin Fine Sciences Ltd?
Camlin Fine Sciences Ltd reported a return on equity of -3.15%. Its debt-to-equity ratio is 0.69.
Company Information
Camlin Fine Sciences is engaged in the Business of Speciality Chemicals.
Website camlinfs.com
CEO Mr. Ashish Subhash Dandekar
Employees 661
Listed 2007-03-30
Face Value ₹ 1
Issued Size 19,20,86,613
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CAMLINFINE.md for Camlin Fine Sciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.